New‐onset atypical fulminant type 1 diabetes after COVID‐19 vaccination: A case report
Takaaki Kobayashi, Fumiyoshi Yakou, Masuo Saburi, Ai Hirose, Hiroaki Akaoka, Yusuke Hirota, Daisuke Yunaiyama, Nobuteru Asahi, Atsushi Ohno, Takaya Matsushita
Abstract
Adverse reactions, including the onset of diabetes, after coronavirus disease 2019 (COVID-19) vaccination have been reported. Herein, we report a case of a man who developed anti-glutamic acid decarboxylase (GAD) antibody-positive fulminant type 1 diabetes 15 weeks after COVID-19 vaccination, atypical of the previously reported anti-GAD antibody-negative cases.
Topics & Concepts
MedicineFulminantVaccinationType 1 diabetesCoronavirus disease 2019 (COVID-19)Diabetes mellitusAntibodyImmunologyDiseaseGlutamate decarboxylasePediatricsInternal medicineInfectious disease (medical specialty)EndocrinologyEnzymeChemistryBiochemistryDiabetes and associated disordersSARS-CoV-2 and COVID-19 ResearchAutoimmune Neurological Disorders and Treatments